582 related articles for article (PubMed ID: 24433082)
1. Loss of bone morphogenetic protein receptor 2 is associated with abnormal DNA repair in pulmonary arterial hypertension.
Li M; Vattulainen S; Aho J; Orcholski M; Rojas V; Yuan K; Helenius M; Taimen P; Myllykangas S; De Jesus Perez V; Koskenvuo JW; Alastalo TP
Am J Respir Cell Mol Biol; 2014 Jun; 50(6):1118-28. PubMed ID: 24433082
[TBL] [Abstract][Full Text] [Related]
2. Endothelin-Bone morphogenetic protein type 2 receptor interaction induces pulmonary artery smooth muscle cell hyperplasia in pulmonary arterial hypertension.
Maruyama H; Dewachter C; Belhaj A; Rondelet B; Sakai S; Remmelink M; Vachiery JL; Naeije R; Dewachter L
J Heart Lung Transplant; 2015 Mar; 34(3):468-78. PubMed ID: 25447587
[TBL] [Abstract][Full Text] [Related]
3. BMPR2 Loss Activates AKT by Disrupting DLL4/NOTCH1 and PPARγ Signaling in Pulmonary Arterial Hypertension.
Awad KS; Wang S; Dougherty EJ; Keshavarz A; Demirkale CY; Yu ZX; Miller L; Elinoff JM; Danner RL
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791441
[TBL] [Abstract][Full Text] [Related]
4. CCL5 deficiency rescues pulmonary vascular dysfunction, and reverses pulmonary hypertension via caveolin-1-dependent BMPR2 activation.
Nie X; Tan J; Dai Y; Liu Y; Zou J; Sun J; Ye S; Shen C; Fan L; Chen J; Bian JS
J Mol Cell Cardiol; 2018 Mar; 116():41-56. PubMed ID: 29374556
[TBL] [Abstract][Full Text] [Related]
5. Bone morphogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival: implications for loss-of-function mutations in the pathogenesis of pulmonary hypertension.
Teichert-Kuliszewska K; Kutryk MJ; Kuliszewski MA; Karoubi G; Courtman DW; Zucco L; Granton J; Stewart DJ
Circ Res; 2006 Feb; 98(2):209-17. PubMed ID: 16357305
[TBL] [Abstract][Full Text] [Related]
6. Codependence of Bone Morphogenetic Protein Receptor 2 and Transforming Growth Factor-β in Elastic Fiber Assembly and Its Perturbation in Pulmonary Arterial Hypertension.
Tojais NF; Cao A; Lai YJ; Wang L; Chen PI; Alcazar MAA; de Jesus Perez VA; Hopper RK; Rhodes CJ; Bill MA; Sakai LY; Rabinovitch M
Arterioscler Thromb Vasc Biol; 2017 Aug; 37(8):1559-1569. PubMed ID: 28619995
[TBL] [Abstract][Full Text] [Related]
7. [Bone morphogenetic protein type II receptor gene promoter mutation-142G > A in a patient with familial pulmonary arterial hypertension].
Li W; Hu H
Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(4):230-4. PubMed ID: 19552837
[TBL] [Abstract][Full Text] [Related]
8. Raf/ERK drives the proliferative and invasive phenotype of BMPR2-silenced pulmonary artery endothelial cells.
Awad KS; Elinoff JM; Wang S; Gairhe S; Ferreyra GA; Cai R; Sun J; Solomon MA; Danner RL
Am J Physiol Lung Cell Mol Physiol; 2016 Jan; 310(2):L187-201. PubMed ID: 26589479
[TBL] [Abstract][Full Text] [Related]
9. Role of apoptosis in pulmonary hypertension: from experimental models to clinical trials.
Jurasz P; Courtman D; Babaie S; Stewart DJ
Pharmacol Ther; 2010 Apr; 126(1):1-8. PubMed ID: 20117135
[TBL] [Abstract][Full Text] [Related]
10. Bmpr2 Mutant Rats Develop Pulmonary and Cardiac Characteristics of Pulmonary Arterial Hypertension.
Hautefort A; Mendes-Ferreira P; Sabourin J; Manaud G; Bertero T; Rucker-Martin C; Riou M; Adão R; Manoury B; Lambert M; Boet A; Lecerf F; Domergue V; Brás-Silva C; Gomez AM; Montani D; Girerd B; Humbert M; Antigny F; Perros F
Circulation; 2019 Feb; 139(7):932-948. PubMed ID: 30586714
[TBL] [Abstract][Full Text] [Related]
11. Phenotypically Silent Bone Morphogenetic Protein Receptor 2 Mutations Predispose Rats to Inflammation-Induced Pulmonary Arterial Hypertension by Enhancing the Risk for Neointimal Transformation.
Tian W; Jiang X; Sung YK; Shuffle E; Wu TH; Kao PN; Tu AB; Dorfmüller P; Cao A; Wang L; Peng G; Kim Y; Zhang P; Chappell J; Pasupneti S; Dahms P; Maguire P; Chaib H; Zamanian R; Peters-Golden M; Snyder MP; Voelkel NF; Humbert M; Rabinovitch M; Nicolls MR
Circulation; 2019 Oct; 140(17):1409-1425. PubMed ID: 31462075
[TBL] [Abstract][Full Text] [Related]
12. In Pulmonary Arterial Hypertension, Reduced BMPR2 Promotes Endothelial-to-Mesenchymal Transition via HMGA1 and Its Target Slug.
Hopper RK; Moonen JR; Diebold I; Cao A; Rhodes CJ; Tojais NF; Hennigs JK; Gu M; Wang L; Rabinovitch M
Circulation; 2016 May; 133(18):1783-94. PubMed ID: 27045138
[TBL] [Abstract][Full Text] [Related]
13. Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension.
Machado RD; Aldred MA; James V; Harrison RE; Patel B; Schwalbe EC; Gruenig E; Janssen B; Koehler R; Seeger W; Eickelberg O; Olschewski H; Elliott CG; Glissmeyer E; Carlquist J; Kim M; Torbicki A; Fijalkowska A; Szewczyk G; Parma J; Abramowicz MJ; Galie N; Morisaki H; Kyotani S; Nakanishi N; Morisaki T; Humbert M; Simonneau G; Sitbon O; Soubrier F; Coulet F; Morrell NW; Trembath RC
Hum Mutat; 2006 Feb; 27(2):121-32. PubMed ID: 16429395
[TBL] [Abstract][Full Text] [Related]
14. MED1 Regulates BMP/TGF-β in Endothelium: Implication for Pulmonary Hypertension.
Wang C; Xing Y; Zhang J; He M; Dong J; Chen S; Wu H; Huang HY; Chou CH; Bai L; He F; She J; Su A; Wang Y; Thistlethwaite PA; Huang HD; Yuan JX; Yuan ZY; Shyy JY
Circ Res; 2022 Oct; 131(10):828-841. PubMed ID: 36252121
[TBL] [Abstract][Full Text] [Related]
15. Targeted gene delivery of BMPR2 attenuates pulmonary hypertension.
Reynolds AM; Holmes MD; Danilov SM; Reynolds PN
Eur Respir J; 2012 Feb; 39(2):329-43. PubMed ID: 21737550
[TBL] [Abstract][Full Text] [Related]
16. BMPR2 gene delivery reduces mutation-related PAH and counteracts TGF-β-mediated pulmonary cell signalling.
Feng F; Harper RL; Reynolds PN
Respirology; 2016 Apr; 21(3):526-32. PubMed ID: 26689975
[TBL] [Abstract][Full Text] [Related]
17. Modulation of Endothelial Bone Morphogenetic Protein Receptor Type 2 Activity by Vascular Endothelial Growth Factor Receptor 3 in Pulmonary Arterial Hypertension.
Hwangbo C; Lee HW; Kang H; Ju H; Wiley DS; Papangeli I; Han J; Kim JD; Dunworth WP; Hu X; Lee S; El-Hely O; Sofer A; Pak B; Peterson L; Comhair S; Hwang EM; Park JY; Thomas JL; Bautch VL; Erzurum SC; Chun HJ; Jin SW
Circulation; 2017 Jun; 135(23):2288-2298. PubMed ID: 28356442
[TBL] [Abstract][Full Text] [Related]
18. PPARγ-p53-Mediated Vasculoregenerative Program to Reverse Pulmonary Hypertension.
Hennigs JK; Cao A; Li CG; Shi M; Mienert J; Miyagawa K; Körbelin J; Marciano DP; Chen PI; Roughley M; Elliott MV; Harper RL; Bill MA; Chappell J; Moonen JR; Diebold I; Wang L; Snyder MP; Rabinovitch M
Circ Res; 2021 Feb; 128(3):401-418. PubMed ID: 33322916
[TBL] [Abstract][Full Text] [Related]
19. Autophagy contributes to BMP type 2 receptor degradation and development of pulmonary arterial hypertension.
Gomez-Puerto MC; van Zuijen I; Huang CJ; Szulcek R; Pan X; van Dinther MA; Kurakula K; Wiesmeijer CC; Goumans MJ; Bogaard HJ; Morrell NW; Rana AA; Ten Dijke P
J Pathol; 2019 Nov; 249(3):356-367. PubMed ID: 31257577
[TBL] [Abstract][Full Text] [Related]
20. Genetic ablation of the BMPR2 gene in pulmonary endothelium is sufficient to predispose to pulmonary arterial hypertension.
Hong KH; Lee YJ; Lee E; Park SO; Han C; Beppu H; Li E; Raizada MK; Bloch KD; Oh SP
Circulation; 2008 Aug; 118(7):722-30. PubMed ID: 18663089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
